These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 8993080)

  • 41. The problem of delusional ugliness: is it really body dysmorphic disorder?
    Fontenelle LF; Mendlowicz MV; Kalaf J; Versiani M
    World J Biol Psychiatry; 2006; 7(2):110-5. PubMed ID: 16684683
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Body dysmorphic disorder--dysmorphophobia].
    Jakubietz M; Jakubietz R; Grünert J
    Zentralbl Chir; 2007 Feb; 132(1):38-43. PubMed ID: 17304434
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Body dysmorphic disorder: Symptoms, prevalence, assessment and treatment].
    Hardardottir H; Hauksdottir A; Bjornsson AS
    Laeknabladid; 2019 Mar; 105(3):125-131. PubMed ID: 30806630
    [TBL] [Abstract][Full Text] [Related]  

  • 44. An open-label trial of venlafaxine in body dysmorphic disorder.
    Allen A; Hadley SJ; Kaplan A; Simeon D; Friedberg J; Priday L; Baker BR; Greenberg JL; Hollander E
    CNS Spectr; 2008 Feb; 13(2):138-44. PubMed ID: 18227745
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Body dysmorphic disorder and cosmetic surgery: assessment of 24 subjects with a minimal defect in appearance 5 years after their request for cosmetic surgery].
    Biraben-Gotzamanis L; Aouizerate B; Martin-Guehl C; Grabot D; Tignol J
    Presse Med; 2009; 38(7-8):1062-7. PubMed ID: 19359130
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Weak antidepressant response after buspirone augmentation of serotonin reuptake inhibitors in refractory severe depression.
    Fischer P; Tauscher J; Küfferle B; Kasper S
    Int Clin Psychopharmacol; 1998 Mar; 13(2):83-6. PubMed ID: 9669189
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Body dysmorphic disorder: does it have a psychotic subtype?
    McElroy SL; Phillips KA; Keck PE; Hudson JI; Pope HG
    J Clin Psychiatry; 1993 Oct; 54(10):389-95. PubMed ID: 8262881
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacotherapy in body dysmorphic disorder: relapse prevention and novel treatments.
    Dong N; Nezgovorova V; Hong K; Hollander E
    Expert Opin Pharmacother; 2019 Jul; 20(10):1211-1219. PubMed ID: 31038370
    [No Abstract]   [Full Text] [Related]  

  • 49. Body dysmorphic disorder: a clinician's introduction.
    Regan L; Dufresne RG; Phillips K
    Med Health R I; 2001 Sep; 84(9):292-3. PubMed ID: 11565276
    [No Abstract]   [Full Text] [Related]  

  • 50. Patients with severe depression may benefit from buspirone augmentation of selective serotonin reuptake inhibitors: results from a placebo-controlled, randomized, double-blind, placebo wash-in study.
    Appelberg BG; Syvälahti EK; Koskinen TE; Mehtonen OP; Muhonen TT; Naukkarinen HH
    J Clin Psychiatry; 2001 Jun; 62(6):448-52. PubMed ID: 11465522
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Body image disturbance in body dysmorphic disorder and eating disorders. Obsessions or delusions?
    Phillips KA; Kim JM; Hudson JI
    Psychiatr Clin North Am; 1995 Jun; 18(2):317-34. PubMed ID: 7659601
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Results of long-term observation (3-11 years) of patients with dual diagnosis: body dysmorphic disorder and delusional disorder, somatic type].
    Rabe-Jabłońska J
    Psychiatr Pol; 1998; 32(2):143-53. PubMed ID: 9640983
    [TBL] [Abstract][Full Text] [Related]  

  • 53. In pursuit of perfection: a primary care physician's guide to body dysmorphic disorder.
    Slaughter JR; Sun AM
    Am Fam Physician; 1999 Oct; 60(6):1738-42. PubMed ID: 10537388
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Insight in obsessive compulsive disorder and body dysmorphic disorder.
    Eisen JL; Phillips KA; Coles ME; Rasmussen SA
    Compr Psychiatry; 2004; 45(1):10-5. PubMed ID: 14671731
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Aripiprazole as an augmentation agent in treatment-resistant body dysmorphic disorder.
    Uzun O; Ozdemir B
    Clin Drug Investig; 2010; 30(10):707-10. PubMed ID: 20701402
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Buspirone is an effective augmenting agent of serotonin selective re-uptake inhibitors in severe treatment-refractory depression.
    Bouwer C; Stein DJ
    S Afr Med J; 1997 Apr; 87(4 Suppl):534-7, 540. PubMed ID: 9180827
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Understanding and treating body dysmorphic disorder.
    Singh AR; Veale D
    Indian J Psychiatry; 2019 Jan; 61(Suppl 1):S131-S135. PubMed ID: 30745686
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Buspirone: future directions.
    Apter JT; Allen LA
    J Clin Psychopharmacol; 1999 Feb; 19(1):86-93. PubMed ID: 9934947
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Body dysmorphic disorder.
    Fang A; Matheny NL; Wilhelm S
    Psychiatr Clin North Am; 2014 Sep; 37(3):287-300. PubMed ID: 25150563
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Suicidality in a placebo-controlled fluoxetine study of body dysmorphic disorder.
    Phillips KA; Kelly MM
    Int Clin Psychopharmacol; 2009 Jan; 24(1):26-8. PubMed ID: 19060721
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.